By mimicking the natural GLP-1 hormone, it targets areas of the brain that regulate appetite
Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, et al
While compromised barriers pathological, creates opportunity for peptide therapy during active disease phases
The absence of dry mouth from formal adverse effect profiles does not definitively exclude the possibility that some patients may experience this symptom, as individual responses to medications can vary considerably based on genetic factors, concurrent medications, and underlying health conditions
Although previous studies showed a lack of therapeutic benefit for GIP agonists, current studies show that the glucose lowering and weight loss effects of tirzepatide are at least as effective as GLP-1 RAs with a similar adverse effect profile
GLP-1 receptor expression in the nervous system GLP-1 receptors are not limited to the pancreas and gut